Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | CASP1 | P29466 | 1/20 | 0.67 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.67 |
| ▸ | CASP7 | P55210 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | FLT3 | P36888 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16795786 | 0.86 | ALDH1A1 (0.53) | LMNAKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL2704996 | 0.84 | NPC1 (0.49) | LMNAKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL30419935 | 0.84 | PIM1 (0.64) | LMNAKDM4EALDH1A1HSD17B10GLA | |
| SCHEMBL2897831 | 0.84 | PIM1 (0.64) | LMNAKDM4EALDH1A1HSD17B10GLA | |
| SCHEMBL23875930 | 0.82 | NPC1 (0.47) | LMNAKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL22276177 | 0.81 | CHRNA7 (0.47) | LMNAKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL30136785 | 0.81 | KDM4E (0.45) | LMNAKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL24757682 | 0.81 | KDM4E (0.45) | LMNAKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL29404836 | 0.81 | CHRNA7 (0.47) | LMNAKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL29051332 | 0.81 | CHRNA7 (0.55) | KDM4EALDH1A1GAAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257395-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-08-17 | — | — | US | disclosed |
| US-20230257395-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-08-17 | — | — | US | disclosed |
| US-11661430-B2 | Tetrazole derivatives as TRPA1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-05-30 | — | — | US | disclosed |
| US-11661427-B2 | Tetrazole derivatives as TRPA1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-05-30 | — | — | US | disclosed |
| US-11661427-B2 | Tetrazole derivatives as TRPA1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-05-30 | — | — | US | disclosed |
| US-11661430-B2 | Tetrazole derivatives as TRPA1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-05-30 | — | — | US | disclosed |
| US-11578080-B2 | Thienopyrimidones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-02-14 | — | — | US | disclosed |
| WO-2022079092-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022079091-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-21 | — | — | WO | disclosed |
| US-20220112210-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2022-04-14 | — | — | US | disclosed |
| US-9802927-B2 | Oxadiazine compounds and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802927-B2 | Oxadiazine compounds and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802927-B2 | Oxadiazine compounds and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-03-09 | — | — | US | disclosed |
| WO-2016201168-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | FORUM PHARMCEUTICALS INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| WO-2015087094-A1 | NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SEMMELWEIS EGYETEM (HU) | 2015-06-18 | — | — | WO | disclosed |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| WO-2012048058-A2 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | J-PHARMA CO., LTD. (JP) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578080-B2 | Thienopyrimidones | TRPA1, TRPV1, TRPV2 | LMNA 4151/4885KDM4E 3740/4885ALDH1A1 822/4885 |
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | PSEN2, SMN1; SMN2, OTC | LMNA 2961/4885KDM4E 3178/4885ALDH1A1 1137/4885 |
| US-20230257395-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | TRPA1, TRPV1, TRPV5 | LMNA 3384/4885KDM4E 4765/4885ALDH1A1 1326/4885 |
| US-20220112210-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | TRPA1, TRPV1, TRPV5 | LMNA 3384/4885KDM4E 4765/4885ALDH1A1 1326/4885 |
| US-11661427-B2 | Tetrazole derivatives as TRPA1 inhibitors | TRPA1, TRPV1, TRPV5 | LMNA 3570/4885KDM4E 4764/4885ALDH1A1 1265/4885 |
| US-11661430-B2 | Tetrazole derivatives as TRPA1 inhibitors | TRPA1, TRPV1, TRPV5 | LMNA 3570/4885KDM4E 4764/4885ALDH1A1 1265/4885 |
| US-20130225673-A1 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION | SLCO2B1, SLCO2A1, SLC10A6 | LMNA 3361/4885KDM4E 3333/4885ALDH1A1 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.